ArticleJournal of orthopaedic surgery and research2026
Application of gut microbiota metabolites in the treatment of knee osteoarthritis: a network pharmacology study.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKnee osteoarthritis (KOA) is a prevalent degenerative joint disease affecting approximately 654 million people worldwide. The gut-joint axis theory suggests a intrinsic link between gut microbiota(GM) metabolites and KOA pathogenesis. This study employs network pharmacology to investigate the protective effects of GM metabolites against KOA and elucidate their underlying molecular mechanisms.
methodsKOA-related targets and GM metabolite targets were retrieved from public databases. After deduplication, intersecting targets were identified and subjected to protein-protein interaction (PPI) network analysis, Gene Ontology (GO) enrichment, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to identify core targets and pathways. Functional association analysis was performed on core targets, followed by GO, KEGG, and functional clustering analyses. Results from both analytical rounds were compared. A "Gut Microbiota-Target-Metabolite" network was constructed to screen key metabolites and targets, which were subsequently validated using molecular docking, drug-like property assessment, and toxicity analysis.
resultsBy integrating multi-source target prediction, network analysis, and molecular docking validation, this study first identified IL6, IL1B, and NFKB1 as core targets regulating KOA processes via GM metabolites. GO analysis revealed their functions primarily concentrate on immune response and inflammatory regulation. KEGG analysis highlighted the lipid and atherosclerosis pathway and TNF signaling pathway as key mechanisms. Butyrate, acetate, propionate, and trimethylamine oxide emerged as core metabolites. Molecular docking confirmed strong binding affinities with core targets. All four metabolites exhibited favorable bioavailability, acceptable Lipinski's rule violations, and no hepatotoxicity or carcinogenicity.
conclusionThis study provides novel network pharmacology evidence supporting the gut-joint axis theory, revealing a potential mechanism whereby GM metabolites may synergistically intervene in KOA through multiple targets and pathways. It also identifies candidate targets and metabolites for gut microbiome-based prevention and treatment strategies for KOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.